Anil Singhal

Dr. Singhal is the President and CEO of Trishula Therapeutics, bringing with him more than three decades of research and development leadership experience in the biopharmaceutical industry. He also serves on the Board of Directors for Trishula and TriSalus Inc.

He joins Trishula from Adicet Bio where, as the President and CEO, he led the company to its first oncology IND and merger with a public company. Previously, Dr. Singhal held the positions of Executive in Residence at Canaan Partners and CSO at OncoResponse Inc. Dr. Singhal also served as Vice President of Early Oncology Development at AbbVie and Head of the AbbVie Redwood City site. In that role, he led the global approval of Empliciti in multiple myeloma and daclizumab in MS. As a member of the R&D leadership team, he helped to build an impressive portfolio and key translational science capabilities in oncology, immunology and other diseases.

Prior to his industry tenure, Dr. Singhal was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington.